Nucleic Acid Therapeutics CDMO Market
完整報告名稱與涵蓋範圍
Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Technology (Column-Based Method, Microarray-Based Method), By Product, By End-User (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories), By Region, And By Segment Forecasts, 2025-2034
報告摘要
Valued at USD 2,540.9 Million as of 2024, the global Nucleic Acid Therapeutics CDMO Market is poised to climb to USD 8,688.2 Million by 2034, reflecting a compound annual growth rate of 13.2% over the 2025–2034 period.
At its core, Nucleic Acid Therapeutics CDMO pertains to key industry insights & findings from the report:
A robust pipeline of nucleic acid-based drugs and high levels of investment from pharmaceutical companies and venture capitalists are boosting the ma. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened call for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nucleic Acid Therapeutics CDMO Market Snapshot
Chapter 4. Global Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. By Technology & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
5.2.1. Column-Based Method
5.2.2. Microarray-Based Method
Chapter 6. Market Segmentation 2: By Products Estimates & Trend Analysis
6.1. By Products & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
6.2.1. Standard Nucleic Acid
6.2.2. Micro-Scale Nucleic Acid
6.2.3. Large-Scale Nucleic Acid
6.2.4. Custom Nucleic Acid
6.2.5. Modified Nucleic Acid
6.2.6. Primers
6.2.7. Probes
6.2.8. Other Nucleic Acid
6.2.9. Other Services
Chapter 7. Market Segmentation 3: By End-user Estimates & Trend Analysis
7.1. By End-user & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-user:
7.2.1. Pharmaceutical Companies
7.2.2. Academic Research Institute
7.2.3. Diagnostic Laboratories
Chapter 8. Nucleic Acid Therapeutics CDMO Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts By Technology, 2021-2034
8.1.2. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.3. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2021-2034
8.1.4. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, 2021-2034
8.2.2. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, 2021-2034
8.2.3. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2021-2034
8.2.4. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, 2021-2034
8.3.2. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, 2021-2034
8.3.3. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2021-2034
8.3.4. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, (US$ Million) 2021-2034
8.4.2. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.3. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2021-2034
8.4.4. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2021-2034
8.5.4. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Agilent Technologies, Inc.
9.2.2. Ajinomoto Co. Inc.
9.2.3. Bachem Holding AG.
9.2.4. Biospring GmbH
9.2.5. Corden Pharma International
9.2.6. Danaher Corporation
9.2.7. Guangzhou Ruibo Biotechnology Co., Ltd.
9.2.8. KNC Laboratories Co., Ltd.
9.2.9. LGC Limited
9.2.10. Merck KGaA
9.2.11. Nippon Shokubai Co., Ltd.
9.2.12. Nitto Denko Avecia Inc.
9.2.13. QIAGEN N.V.
9.2.14. ST Pharm Co Ltd
9.2.15. Sumitomo Chemical Co., Ltd.
9.2.16. Syngene International Limited
9.2.17. Thermo Fisher Scientific Inc.
9.2.18. Wuxi AppTec
9.2.19. Yamasa Corporation
9.2.20. Laboratorios Farmacéuticos Rovi, S.A.
9.2.21. Sartorius AG (BIA Separations)
9.2.22. AGC Biologics
9.2.23. FUJIFILM Diosynth Biotechnologies
9.2.24. Hanmi Pharmaceutical
9.2.25. Arranta Bio (Recipharm)
9.2.26. ST Pharm
9.2.27. BioCina Pty Ltd.
9.2.28. Curia Global, Inc.
9.2.29. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們